EFFICACY AND DIRECT MEDICAL COSTS OF METFORMIN-GLIBENCLAMIDE TREATMENT IN ECUADORIAN POPULATION WITH TYPE II DIABETES MELLITUS DURING THE COVID-19 PANDEMIC

Adult T2DM patients treated with MG combination from January to December 2021 were included. Patient chart’s information was collected using a Capture Report Form to evaluate the efficacy and management of these outpatients. Drug and services prices were taken from the National Public Procurement Service, while medical cost estimations were obtained from the National Fare System (2014 and 2019). A Microsoft Excel budget model was developed to calculate the DMC. The study was approved by the Institutional Review Board Ethics Committee